1135 related articles for article (PubMed ID: 15055210)
1. Voriconazole: new preparation. Invasive aspergillosis: benefits to be confirmed.
Prescrire Int; 2004 Feb; 13(69):13-6. PubMed ID: 15055210
[TBL] [Abstract][Full Text] [Related]
2. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.
Herbrecht R; Denning DW; Patterson TF; Bennett JE; Greene RE; Oestmann JW; Kern WV; Marr KA; Ribaud P; Lortholary O; Sylvester R; Rubin RH; Wingard JR; Stark P; Durand C; Caillot D; Thiel E; Chandrasekar PH; Hodges MR; Schlamm HT; Troke PF; de Pauw B;
N Engl J Med; 2002 Aug; 347(6):408-15. PubMed ID: 12167683
[TBL] [Abstract][Full Text] [Related]
3. [Treatment of invasive fungal infections with voriconazole. Evaluation of experience with compassionate use of voriconazole in Spain].
Díaz Pedroche C; Cisneros JM; Lumbreras C; Aguado JM;
Rev Esp Quimioter; 2005 Jun; 18(2):149-58. PubMed ID: 16130037
[TBL] [Abstract][Full Text] [Related]
4. Voriconazole -- better chances for patients with invasive mycoses.
Ghannoum MA; Kuhn DM
Eur J Med Res; 2002 May; 7(5):242-56. PubMed ID: 12069915
[TBL] [Abstract][Full Text] [Related]
5. Voriconazole: a new triazole antifungal agent.
Johnson LB; Kauffman CA
Clin Infect Dis; 2003 Mar; 36(5):630-7. PubMed ID: 12594645
[TBL] [Abstract][Full Text] [Related]
6. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome.
Patterson TF; Boucher HW; Herbrecht R; Denning DW; Lortholary O; Ribaud P; Rubin RH; Wingard JR; DePauw B; Schlamm HT; Troke P; Bennett JE; ;
Clin Infect Dis; 2005 Nov; 41(10):1448-52. PubMed ID: 16231256
[TBL] [Abstract][Full Text] [Related]
7. Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis.
Howard A; Hoffman J; Sheth A
Ann Pharmacother; 2008 Dec; 42(12):1859-64. PubMed ID: 19017830
[TBL] [Abstract][Full Text] [Related]
8. Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis.
Sambatakou H; Dupont B; Lode H; Denning DW
Am J Med; 2006 Jun; 119(6):527.e17-24. PubMed ID: 16750972
[TBL] [Abstract][Full Text] [Related]
9. Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia.
Shehab N; DePestel DD; Mackler ER; Collins CD; Welch K; Erba HP
Pharmacotherapy; 2007 Jul; 27(7):970-9. PubMed ID: 17594202
[TBL] [Abstract][Full Text] [Related]
10. [Experience with voriconazole in invasive aspergillosis].
Thiel E; Schwartz S
Mycoses; 2003; 46 Suppl 2():3-7. PubMed ID: 15055137
[TBL] [Abstract][Full Text] [Related]
11. Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients.
Berge M; Guillemain R; Boussaud V; Pham MH; Chevalier P; Batisse A; Amrein C; Dannaoui E; Loriot MA; Lillo-Le Louet A; Billaud EM
Transpl Infect Dis; 2009 Jun; 11(3):211-9. PubMed ID: 19302272
[TBL] [Abstract][Full Text] [Related]
12. Successsful voriconazole treatment of disseminated fusarium infection in an immunocompromised patient.
Consigny S; Dhedin N; Datry A; Choquet S; Leblond V; Chosidow O
Clin Infect Dis; 2003 Jul; 37(2):311-3. PubMed ID: 12856225
[TBL] [Abstract][Full Text] [Related]
13. Caspofungin: new indication. No progress in invasive candidiasis.
Prescrire Int; 2004 Apr; 13(70):48-9. PubMed ID: 15148956
[TBL] [Abstract][Full Text] [Related]
14. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.
Pascual A; Calandra T; Bolay S; Buclin T; Bille J; Marchetti O
Clin Infect Dis; 2008 Jan; 46(2):201-11. PubMed ID: 18171251
[TBL] [Abstract][Full Text] [Related]
15. Pseudoporphyria as a result of voriconazole use: a case report.
Dolan CK; Hall MA; Blazes DL; Norwood CW
Int J Dermatol; 2004 Oct; 43(10):768-71. PubMed ID: 15485539
[TBL] [Abstract][Full Text] [Related]
16. Voriconazole treatment for less-common, emerging, or refractory fungal infections.
Perfect JR; Marr KA; Walsh TJ; Greenberg RN; DuPont B; de la Torre-Cisneros J; Just-Nübling G; Schlamm HT; Lutsar I; Espinel-Ingroff A; Johnson E
Clin Infect Dis; 2003 May; 36(9):1122-31. PubMed ID: 12715306
[TBL] [Abstract][Full Text] [Related]
17. Combined therapy in treatment of murine infection by Fusarium solani.
Ruíz-Cendoya M; Mariné M; Guarro J
J Antimicrob Chemother; 2008 Sep; 62(3):543-6. PubMed ID: 18495651
[TBL] [Abstract][Full Text] [Related]
18. Voriconazole: a broad-spectrum triazole for the treatment of invasive fungal infections.
Cecil JA; Wenzel RP
Expert Rev Hematol; 2009 Jun; 2(3):237-54. PubMed ID: 21082966
[TBL] [Abstract][Full Text] [Related]
19. Oral voriconazole for empiric antifungal treatment in patients with uncomplicated febrile neutropenia.
Przepiorka D; Buadi FK; McClune B
Pharmacotherapy; 2008 Jan; 28(1):58-63. PubMed ID: 18154475
[TBL] [Abstract][Full Text] [Related]
20. Salvage therapy with voriconazole for invasive fungal infections in patients failing or intolerant to standard antifungal therapy.
Baden LR; Katz JT; Fishman JA; Koziol C; DelVecchio A; Doran M; Rubin RH
Transplantation; 2003 Dec; 76(11):1632-7. PubMed ID: 14702539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]